A multiple-dose study design with achievement of steady state for each of the three treatments would have required at least 5 weeks per treatment period because of the long half-life of approximately 1 week for both icodec and semaglutide
A possible reason for this is that there is a higher background concentration of carnitine in muscle than in the liver, or that the degree of supplementation with l- and d-carnitine was insufficient to significantly alter the concentration of acyl-carnitine, such that any change in lipid metabolism in muscle was not obvious
And thats why we won that award. The Vikings had fun with final touches on the design, too
Convenience is the absolute primary driver and systemic effects are a secondary, or even non-existent, concern
What this guide gives readers, that most microinfusion articles don't, is a molecule-by-molecule, mechanism-by-mechanism breakdown